These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36423044)

  • 41. Vaccine value profile for Neisseria gonorrhoeae.
    Lyu Y; Choong A; Chow EPF; Seib KL; Marshall HS; Unemo M; de Voux A; Wang B; Miranda AE; Gottlieb SL; Mello MB; Wi T; Baggaley R; Marshall C; Abu-Raddad LJ; Abara WE; Chen XS; Ong JJ
    Vaccine; 2024 Jul; 42(19S1):S42-S69. PubMed ID: 38123397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure of the Recombinant
    Almonacid-Mendoza HL; Humbert MV; Dijokaite A; Cleary DW; Soo Y; Hung MC; Orr CM; Machelett MM; Tews I; Christodoulides M
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30305317
    [No Abstract]   [Full Text] [Related]  

  • 43. Evaluating vaccine-elicited antibody activities against
    Gray MC; Thomas KS; Lamb ER; Werner LM; Connolly KL; Jerse AE; Criss AK
    bioRxiv; 2023 Aug; ():. PubMed ID: 37577557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.
    Watson PS; Novy PL; Friedland LR
    Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Ahoure M; Denehy E; Flood L; Marshall H
    J Infect; 2023 Aug; 87(2):95-102. PubMed ID: 37268223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB).
    Marshall GS; Abbing-Karahagopian V; Marshall HS; Cenci S; Conway JH; Occhipinti E; Bekkat-Berkani R; Banzhoff A; Sohn WY
    Expert Rev Vaccines; 2023; 22(1):530-544. PubMed ID: 37278390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Broad vaccine protection against Neisseria meningitidis using factor H binding protein.
    Findlow J; Bayliss CD; Beernink PT; Borrow R; Liberator P; Balmer P
    Vaccine; 2020 Nov; 38(49):7716-7727. PubMed ID: 32878710
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complement interactions with the pathogenic Neisseriae: clinical features, deficiency states, and evasion mechanisms.
    Lewis LA; Ram S
    FEBS Lett; 2020 Aug; 594(16):2670-2694. PubMed ID: 32058583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccines against Meningococcal Diseases.
    Pizza M; Bekkat-Berkani R; Rappuoli R
    Microorganisms; 2020 Oct; 8(10):. PubMed ID: 33022961
    [No Abstract]   [Full Text] [Related]  

  • 51. The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).
    Shea MW
    Ann Med Surg (Lond); 2013; 2(2):53-6. PubMed ID: 25628885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urgent Need to Understand and Prevent Gonococcal Infection: From the Laboratory to Real-World Context.
    Ruiz García Y; Marrazzo J; Martinón-Torres F; Workowski K; Giordano G; Pizza M; Sohn WY
    J Infect Dis; 2024 Oct; 230(4):e758-e767. PubMed ID: 38819303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae.
    Humbert MV; Christodoulides M
    Vaccine; 2018 Jun; 36(27):3926-3936. PubMed ID: 29803329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States.
    Banzhoff A
    Ther Adv Vaccines; 2017 Feb; 5(1):3-14. PubMed ID: 28344804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
    Whittles LK; Didelot X; White PJ
    Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?
    Hong E; Giuliani MM; Deghmane AE; Comanducci M; Brunelli B; Dull P; Pizza M; Taha MK
    Vaccine; 2013 Feb; 31(7):1113-6. PubMed ID: 23261039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
    Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD
    Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model.
    Matthias KA; Connolly KL; Begum AA; Jerse AE; Macintyre AN; Sempowski GD; Bash MC
    J Infect Dis; 2022 Feb; 225(4):650-660. PubMed ID: 34498079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.